IHT Wealth Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

IHT Wealth Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-73	Closed	-$1K	–	961
2018 Q1	$1K	Hold	73	–	–	﹤0.01%	1604
2017 Q4	$1K	Hold	73	–	–	﹤0.01%	1597
2017 Q3	$1K	Hold	73	–	–	﹤0.01%	1329
2017 Q2	$22K	Hold	73	–	–	0.01%	755
2017 Q1	$1K	Hold	73	–	–	﹤0.01%	1184
2016 Q4	$1K	Buy	+73	New	+$1.17K	﹤0.01%	1131

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CLM

ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

SGA

Sector Gamma AS Oslo, Norway $461M AUM 33.26% 1-Year Est. Return

IHT Wealth Management's LXRX Position: Q2 2018 in Review

IHT Wealth Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2018, closing a stake of 73 shares — an estimated $1K sold.

IHT Wealth Management first reported a position in LXRX in Q4 2016 and held it in 6 quarters. The position peaked at $22K in Q2 2017. 121 funds tracked by Wall St. Rank hold LXRX as of Q2 2018.

IHT Wealth Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
IHT Wealth Management sold 73 Lexicon Pharmaceuticals shares in Q2 2018, an estimated $1K.
IHT Wealth Management first reported a position in Lexicon Pharmaceuticals in Q4 2016 and held it in 6 quarters.
IHT Wealth Management's Lexicon Pharmaceuticals position peaked at $22K in Q2 2017.
121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2018.

Based on IHT Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.